Login
Companies $CRSP
$40.61 +$0.24 (0.59%) After hours
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

crisprtx.com

What Do They Do?

Develops CRISPR-based medicines and gene-edited cell therapies for people with blood disorders, cardiovascular disease and other serious conditions.

How Do They Make Money?

revenue
SegmentShareRevenue
Collaboration Revenue
0.0%
FY2022: 36%
Grant Revenue
100%
FY2022: 64%

Do Revenues Turn Into Profits?

No. It lost $581.6M in FY2025.

Operating income, FY2025
−18934% of revenue
▼ −42% (Loss) vs FY2024 (−$466.6M, −1250%)
Net income, FY2025
−16570% of revenue
▼ −59% (Loss) vs FY2024 (−$366.3M, −982%)
Free cash flow, FY2025
−9855% of revenue
▼ −139% (Loss) vs FY2024 (−$144.7M, −388%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +1325%
vs $889K in Q3 FY2025
Net income
▼ −5% (Loss)
vs −$106.4M in Q3 FY2025
Grant Revenue share of revenue vs 100.0% in Q3 FY2025

Shrinking. Revenue fell 100% in 4 years, from $915M in FY2021 to $3.5M in FY2025, about 75% a year.

CAR T adds autoimmune trials The older report outlines CAR T programs for cancer; the latest report also describes trials for autoimmune diseases alongside oncology programs.

Diabetes cell therapy takes a different form The older report described ViaCyte-linked, gene-edited stem-cell candidates for diabetes; the latest describes a beta-cell replacement candidate made from precursor islet cells and says it licensed gene-editing intellectual property to Vertex.

Revenue over time
Collaboration Revenue Grant Revenue
$1B$500M$0

Who Do They Compete With?

Competes with Editas Medicine, Intellia Therapeutics, Metagenomi, Scribe Therapeutics, Beam Therapeutics, Prime Medicine, Tessera Therapeutics, Verve Therapeutics, Allogene Therapeutics, Cellectis, Iovance Biotherapeutics, Factor Bioscience, Korro Bio, nChroma Bio, Precision BioSciences, Sangamo Therapeutics, Tune Therapeutics, Wave Life Sciences, Sarepta Therapeutics, and Alnylam

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support